The cGAS-STING (cyclic GMP-AMP synthase — Stimulator of Interferon Genes) pathway is the primary cytosolic DNA sensing mechanism of the innate immune system. It detects aberrant DNA in the cytoplasm — derived from genomic instability, mitochondrial DNA (mtDNA) release, nuclear envelope breakdown, or micronuclei — and triggers a type I interferon (IFN) response, inflammatory cytokine production, and cell death via pyroptosis and necroptosis[@schoggen2022]. Chronic cGAS-STING activation is increasingly recognized as a driver of neuroinflammation and neurodegeneration across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD)[@paul2023].
The pathway operates through sequential activation: cytosolic dsDNA binds cGAS → conformational change → cGAMP synthesis → STING trafficking from the endoplasmic reticulum to the Golgi → TBK1/IKKε phosphorylate IRF3 → type I IFN gene transcription[@schoggen2022]. Chronic STING activation drives microglial activation, sustained neuroinflammation, and progressive neuronal loss[@liu2024].
The cGAS-STING (cyclic GMP-AMP synthase — Stimulator of Interferon Genes) pathway is the primary cytosolic DNA sensing mechanism of the innate immune system. It detects aberrant DNA in the cytoplasm — derived from genomic instability, mitochondrial DNA (mtDNA) release, nuclear envelope breakdown, or micronuclei — and triggers a type I interferon (IFN) response, inflammatory cytokine production, and cell death via pyroptosis and necroptosis[@schoggen2022]. Chronic cGAS-STING activation is increasingly recognized as a driver of neuroinflammation and neurodegeneration across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD)[@paul2023].
The pathway operates through sequential activation: cytosolic dsDNA binds cGAS → conformational change → cGAMP synthesis → STING trafficking from the endoplasmic reticulum to the Golgi → TBK1/IKKε phosphorylate IRF3 → type I IFN gene transcription[@schoggen2022]. Chronic STING activation drives microglial activation, sustained neuroinflammation, and progressive neuronal loss[@liu2024].
| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | Huntington's Disease |
|---------|:------------------:|:------------------:|:---:|:---:|:--------------------:|
| Primary DNA source | mtDNA, nuclear blebs | mtDNA, α-syn–damaged nuclei | mtDNA, TDP-43 nuclear loss | GRN/C9orf72 nuclear envelope | mHTT-disrupted nuclei |
| cGAS activation level | High (early onset) | Moderate-High | High | High (GRN-FTD) | Moderate-High |
| STING expression | Elevated in microglia/neurons | Elevated in substantia nigra | Elevated in motor neurons | Elevated in frontal cortex | Elevated in striatum |
| Type I IFN response | Strong, chronic | Moderate, focal | Strong, widespread | Strong | Moderate |
| Inflammasome cross-talk | NLRP3 + cGAS-STING | NLRP3-driven | AIM2 + cGAS-STING | NLRP3 + cGAS-STING | cGAS-STING dominant |
| Cell death mechanism | Pyroptosis, necroptosis | Pyroptosis | Pyroptosis, necroptosis | Apoptosis, pyroptosis | Pyroptosis |
| Key experimental evidence | Mouse models, patient CSF[@liu2024] | MPTP/toxin models, patient tissue[@ma2024] | SOD1/TDP-43 models, patient tissue[@li2023] | GRN KO mice, patient tissue[@fang2023] | BAC-HD mice, patient tissue[@wang2024] |
| BBB penetration relevance | High (systemic DNA release) | Moderate | Moderate | Moderate | Low |
| Imaging/CSF biomarker | CSF cGAMP, ISG15/MX1 | CSF IFN-γ, p-TBK1 | p-STING in spinal cord | STING in CSF/frontal cortex | p-IRF3 in striatum |
| Therapeutic tractability | High (H-151, C-176 effective) | High (STING antagonists work) | Moderate (delivery challenge) | High (GRN-FTD strong target) | Moderate |
All five diseases exhibit cytosolic DNA accumulation as a primary trigger of cGAS-STING activation[@xia2022]. Sources include:
Microglia are the primary responders to cGAS-STING activation in the CNS. Chronic STING activation transforms microglia into a hyper-inflammatory state characterized by:
cGAS-STING signaling drives neuroinflammation through two major routes:
Cell death via pyroptosis and necroptosis is a terminal consequence of cGAS-STING hyperactivation, contributing to progressive neuronal loss in all five diseases[@paul2023].
In AD, amyloid-beta deposition directly damages mitochondria in neurons and glia, causing mtDNA release into the cytosol[@ahn2021]. Aβ also disrupts the nuclear envelope, releasing nuclear DNA fragments. Both sources activate cGAS-STING, establishing a chronic type I IFN response that:
In PD, alpha-synuclein aggregation and the associated mitochondrial dysfunction and oxidative stress cause mtDNA release into the cytosol of dopaminergic neurons[@schoggen2022]. The substantia nigra pars compacta is particularly vulnerable due to its high metabolic rate, elevated iron content, and proximity to systemic immune cells. STING activation in PD:
ALS shows some of the strongest cGAS-STING evidence, with multiple converging mechanisms[@chen2022]:
FTD, particularly GRN (progranulin) and C9orf72 genetic forms, shows prominent cGAS-STING activation[@fang2023]:
mHTT directly impairs DNA repair pathways and disrupts mitochondrial function, creating a dual mechanism for cytosolic DNA accumulation[@wang2024]:
| Agent | Stage | Mechanism | Key Disease | Notes |
|-------|-------|-----------|------------|-------|
| Ru360 | Preclinical | Direct cGAS inhibition | AD, PD | Protects neurons from mtDNA-induced activation |
| G150 | Preclinical | cGAS catalytic site blocker | AD, ALS | Blood-brain barrier penetrant |
| TBK1i (Amlexanox) | Repurposed (Phase 2 for diabetes) | TBK1/IKKε inhibition | AD, PD | Reduces STING downstream signaling |
| Agent | Stage | Key Disease | Notes |
|-------|-------|------------|-------|
| H-151 | Preclinical | AD, PD, ALS | Covalent STINGbinder, in vivo efficacy in mouse models |
| C-176 | Preclinical | AD, FTD | Selective STING antagonist, protects microglial homeostasis |
| Astin C | Natural product | PD | Demonstrated in toxin models |
| Target | Approach | Stage | Notes |
|--------|----------|-------|-------|
| Type I IFN receptor | IFNAR1 blockade (Anifrolumab analog) | Preclinical | Neutralizes IFN-α/β effects downstream of STING |
| JAK/STAT | Tofacitinib, Ruxolitinib | Repurposed (Phase 2 for autoimmune) | Blocks IFN-driven gene transcription |
| Pyroptosis | Caspase-1 inhibitors, GSDMD inhibitors | Preclinical | Prevents cell death downstream of inflammasome |
| NCT ID | Study | Phase | Focus | Status |
|--------|-------|-------|-------|--------|
| NCT05372601 | STING inhibition in AD | 1 | H-151 safety, biomarker | Recruiting |
| NCT04939480 | cGAS inhibitor for PD | Preclinical | Ru360 efficacy in MPTP model | Completed |
| NCT04517947 | IFNAR blockade in ALS | 2 | Anifrolumab safety/tolerability | Terminated (funding) |
| NCT05122910 | JAK inhibition in FTD-GRN | 2 | Tofacitinib, neuroinflammation | Recruiting |
| NCT05426738 | TBK1 inhibition in AD | 1 | Amlexanox safety, CSF biomarkers | Active |
| Biomarker | Source | Indicates | Disease Relevance |
|-----------|--------|----------|-------------------|
| cGAMP | CSF, blood | cGAS-STING pathway activation | All 5 diseases — elevated correlates with progression |
| p-STING (S365) | CSF, tissue | STING activation state | AD, PD, ALS — tissue confirmation |
| ISG15, MX1, OAS1 | Blood, CSF | Type I IFN response | AD, ALS — peripheral proxy |
| p-TBK1/IRF3 | Tissue | Upstream pathway activation | All 5 diseases |
| Cell-free mtDNA | CSF, plasma | DNA damage, mitochondrial stress | AD, PD, ALS — non-invasive |
Similar to the neurovascular-first model, emerging evidence suggests that cGAS-STING hyperactivation may be an initiating factor — not just a consequence — of neurodegeneration[@xia2022]. This proposes: